$6.20
arrow_drop_down2.97%Key Stats | |
---|---|
Open | $6.42 |
Prev. Close | $6.39 |
EPS | -1.63 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 5.99 | 6.49 |
52 Week Range | 2.09 | 14.84 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.63 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Sprout Social, Altimmune, Equinix, and Globe Life - GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? - The Motley Fool
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics - The Motley Fool